Your session is about to expire
← Back to Search
Alkylating agents
Docetaxel + Carboplatin for Advanced Lung Cancer
Phase 2
Waitlist Available
Research Sponsored by Hope Cancer Institute, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Measurable or evaluable indicator lesion(s) must be completely outside the radiation portal or there must be proof of disease progression
Renal: Creatinine clearance at least 50 mL/min
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying how well giving docetaxel and carboplatin together works in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Who is the study for?
This trial is for adults with advanced non-small cell lung cancer (stages IIIB with pleural effusion or IV). Participants must have measurable disease, normal organ function, and no brain metastases at entry. They should not be pregnant/nursing and must use effective contraception. Prior radiotherapy is okay except in the brain unless there's new growth.Check my eligibility
What is being tested?
The study tests a combination of two chemotherapy drugs, docetaxel and carboplatin, to see how well they work together in treating advanced lung cancer. It's a phase II trial which means it focuses on the effectiveness of this drug combo.See study design
What are the potential side effects?
Common side effects from chemotherapy like docetaxel and carboplatin include fatigue, risk of infection due to low blood counts, nausea, hair loss, numbness or tingling in hands/feet (neuropathy), and allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer can be measured or seen, and is outside the area treated with radiation or has gotten worse.
Select...
My kidneys work well enough (creatinine clearance is 50 mL/min or more).
Select...
My lung cancer is a type called squamous cell bronchioalveolar.
Select...
My cancer has not spread to the lining of my brain and spinal cord.
Select...
My lung cancer is at an advanced stage with fluid in the chest or has spread.
Select...
My cancer is not classified as small cell or carcinoid.
Select...
I am 18 years old or older.
Select...
I do not have cancer that has spread to my brain.
Select...
I can take care of myself and am up and about more than 50% of my waking hours.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Hope Cancer Institute, Inc.Lead Sponsor
3 Previous Clinical Trials
139 Total Patients Enrolled
Raj Sadasivan, MD, PhDStudy ChairHope Cancer Institute, Inc.
3 Previous Clinical Trials
139 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My liver function tests are within the required limits.I can have radiotherapy for my lung cancer and new brain metastases while in the study.I don't have any other illnesses that could interfere with this study.My cancer can be measured or seen, and is outside the area treated with radiation or has gotten worse.My kidneys work well enough (creatinine clearance is 50 mL/min or more).I have not had chemotherapy before and am not receiving any now.My surgery status is not a factor for this trial.My lung cancer is a type called squamous cell bronchioalveolar.My cancer has not spread to the lining of my brain and spinal cord.My lung cancer is at an advanced stage with fluid in the chest or has spread.My treatment plan for biologic therapy is not decided.My treatment plan does not specify hormone therapy.My cancer is a type of large cell adenocarcinoma.My cancer is not classified as small cell or carcinoid.I am 18 years old or older.I do not have cancer that has spread to my brain.I can take care of myself and am up and about more than 50% of my waking hours.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any remaining openings to participate in this research venture?
"The information on clinicaltrials.gov indicates that this trial has stopped recruitment and is no longer accepting applicants. Although it was first published on July 1st 1998, the last update took place December 3rd 2013. Despite its conclusion, there are currently 1628 other trials actively looking for participants to join their studies."
Answered by AI
Has this medical treatment garnered the endorsement of federal agencies?
"Our team at Power has assigned this treatment a safety rating of 2. This is because it only enters into Phase 2 of the clinical trial process, signifying that there are some data indicating its security but no studies validating its efficacy."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger